Litigation Details for Indivior Inc. v. Actavis Laboratories UT, Inc. (D. Del. 2018)
✉ Email this page to a colleague
Indivior Inc. v. Actavis Laboratories UT, Inc. (D. Del. 2018)
| Docket | ⤷ Try a Trial | Date Filed | 2018-04-03 |
| Court | District Court, D. Delaware | Date Terminated | 2019-09-16 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Parties | AQUESTIVE THERAPEUTICS, INC. | ||
| Patents | 9,687,454; 9,855,221; 9,931,305 | ||
| Attorneys | Daniel Sharpe | ||
| Firms | Phillips, McLaughlin & Hall, P.A. | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Indivior Inc. v. Actavis Laboratories UT, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for Indivior Inc. v. Actavis Laboratories UT, Inc. (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | 1 | expiration of United States Patent No. 9,931,305 (“the ’305 patent” or “the patent-in-suit”). …is an action for patent infringement arising under the Food and Drug Laws and Patent Laws of the United… of the ’305 patent, and Plaintiff Indivior is an exclusive licensee of the ’305 patent and holds the…expiration of the ’305 patent, Actavis has committed an act of infringement of the ’305 patent under 35 U.S.C… ’305 patent would infringe one or more claims, including at least claim 26, of the ’305 patent under | External link to document | |
| 2018-05-31 | 14 | Answer to Amended Complaint | infringement, validity, and enforceability of U.S. Patent No. 9,855,221. 10. There is an actual and …the ’305 patent as the assignee. Defendant further admits that, on its face, the ’305 patent is titled… copy of the ’305 patent. Defendant avers that the allegation that the ’305 patent was duly and legally…the ’221 patent as the assignee. Defendant further admits that, on its face, the ’221 patent is titled… copy of the ’221 patent. Defendant avers that the allegation that the ’221 patent was duly and legally | External link to document |
| 2018-06-21 | 21 | Answer to Counterclaim | infringement and validity U.S. Patent No. 9,855,221 (the “’221 patent”). 10. Paragraph 10…infringement and validity of U.S. Patent No. 9,931,305 (the “’305 patent”). Otherwise, Plaintiffs deny Paragraph…Judgment Act, 28 U.S. §§ 2201 and 2202, and the Patent Laws of the United States, 35 U.S.C. §§ 100 et…13. Plaintiffs admit that the ’221 and ’305 patents are listed in the FDA’s Approved Drug Products…products”) before the expiration of the ’221 and ’305 patents. Plaintiffs deny the remainder of the allegations | External link to document |
| 0000-00-00 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,931,305 B2. (fms) (Entered:… 16 September 2019 1:18-cv-00497 835 Patent - Abbreviated New Drug Application(ANDA) | External link to document | |
| 2018-04-30 | 6 | United States Patent Nos. 9,931,305 (“the ’305 patent”) and 9,855,221 (“the ’221 patent”) (collectively…’221 patent, and Plaintiff Indivior is an exclusive licensee of the ’221 patent. The ’221 patent, entitled…is an action for patent infringement arising under the Food and Drug Laws and Patent Laws of the United… of the ’305 patent, and Plaintiff Indivior is an exclusive licensee of the ’305 patent and holds the…expiration of the ’305 patent, Actavis has committed acts of infringement of the ’305 patent under 35 U.S.C. | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
